Selective feticide as a treatment of severe preeclampsia in discordant twins.
Discordant
Feticide
Preeclampsia
Twins
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
19
01
2019
revised:
27
06
2019
accepted:
05
09
2019
pubmed:
10
9
2019
medline:
11
11
2020
entrez:
10
9
2019
Statut:
ppublish
Résumé
Multifetal gestation is often complicated by the development of preeclampsia. In some twin gestations, preeclampsia develops in association with restricted fetal growth of only one fetus. Instead of termination of the entire pregnancy, we investigated an alternative approach to the management of such pregnancies that might allow unharmed survival of the normal twin. We present a case of preeclampsia in twin discordance with severe fetal growth restriction at 25 weeks of gestation. Preeclampsia was linked to a lethal condition in one twin and was treated with selective feticide in an effort to reverse preeclampsia. Inasmuch as the fetal prognosis was extremely poor for the abnormal fetus, selective feticide was a reasonable therapeutic option. Maternal symptoms resolved, allowing continuation of the pregnancy for 4 weeks before delivery of the healthy fetus. We maintain that selective termination induced a decrease in the release of substances involved in the physiopathology of preeclampsia, which allowed the continuation of the pregnancy with close follow-up. This report highlights the link between placental pathology and the disease process of preeclampsia and further supports selective termination as a reasonable management strategy in carefully selected cases of discordant twins.
Identifiants
pubmed: 31499281
pii: S2468-7847(19)30051-0
doi: 10.1016/j.jogoh.2019.101633
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101633Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.